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PPN5
COMPARISON OF COSTS AND
COST-EFFECTIVENESS OF OXCARBAZEPINE 
AND SODIUM VALPROATE FOR
NEW/RECENT ONSET PARTIAL SEIZURES
Bazalo G1, Sachdeo R2, Graham S3, Chang S3, Cohen A3
1Bazalo Consulting, Scottsdale, AZ, USA; 2Robert Wood 
Johnson Medical School, New Brunswick, NJ, USA; 3Novartis 
Pharmaceuticals, East Hanover, NJ, USA
OBJECTIVE: to determine the comparative costs and
cost-effectiveness of oxcarbazepine and sodium valproate
in the treatment of new and recent onset partial epileptic
seizures. METHODS: Low, moderate and high dose
maintenance regimens were determined for each drug
based upon prescription audit information captured in
the prescribing physician’s office. Unit drug costs based
on wholesale acquisition costs were then used to compute
a daily drug cost for each dosage level. A decision-analy-
sis model using a Monte Carlo simulation was developed
to evaluate the cost-effectiveness of oxcarbazepine and
sodium valproate. The model contained the computed
daily drug costs along with direct payer costs associated
with initiation and maintenance of therapy, treatment of
adverse events and switching from one drug to another
due to poor seizure control or adverse events. The proba-
bilities of maintaining seizure control and of experiencing
adverse events were obtained from double-blind clinical
trials comparing oxcarbazepine and sodium valproate.
RESULTS: The average daily drug costs weighted over
the three dosage levels were $4.72 ($1.49 to $7.66) for
oxcarbazepine and $3.17 ($2.45 to $3.87) for sodium
valproate. Total one year costs for oxcarbazepine, includ-
ing costs of adverse events and costs of switching drugs
due to poor seizure control or adverse events were
$3,511 for oxcarbazepine and $5,931 for sodium val-
proate. The computed number of months on initial ther-
apy was 9.95 for oxcarbazepine and 9.66 for sodium val-
proate. The analysis was carried out to four years using
the same probabilities for adverse events and seizure con-
trol. The four-year costs were $17,949 and $23,144 with
25.8 and 24.3 months of therapy for oxcarbazepine and
sodium valproate respectively. CONCLUSION: These
findings suggest that oxcarbazepine results in lower ex-
pected total costs compared to sodium valproate when
drug costs, evaluation and management, adverse events
and costs of switching therapies are taken into account.
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VALIDATION OF THE 24 HOUR HEADACHE 
DISABILITY QUESTIONNAIRE (DISQ-24) IN A 
SAMPLE OF HEADACHE SUFFERERS
Runken MC, Kwong W, Davis K, Batenhorst A
GlaxoSmithKline, Inc, Research Triangle Park, NC, USA
OBJECTIVES: The Disq-24 was developed to measure
headache disability on a 24-hour basis and was first uti-
lized in a sample of migraine subjects who experienced
chronic daily headaches. The purpose of this study was to
evaluate this instrument’s psychometric properties.
METHODS: The Disq-24 is a 14-item questionnaire with
a 6-point Likert-type scale that measures disability with
regards to three hypothesized dimensions: family/social
(4-item), work activities (5-item), and emotions/feelings
(5-item). This instrument was administered in a prospec-
tive, multicenter, randomized, double-blind, placebo-
controlled, parallel group trial of 170 transformed mi-
graine sufferers. Four scaling assumptions of summated
rating scales (equal variances, equal weights, item-inter-
nal consistency and discriminant validity) and scale-level
reliability were examined using the baseline data. RE-
SULTS: The means and standard deviations of items
within each scale were similar. However, item evaluation
demonstrated a floor effect in all items ranging from
22% to 66%. Item internal consistency was generally
high and ranged from 0.62 to 0.90. Cronbach’s alpha
ranged from 0.93 to 0.95 for the three dimensions and
was 0.97 for the total score, exceeding the generally ac-
ceptable criteria of 0.70. Although each item was highly
correlated with the hypothesized scale, the item-scale cor-
relations did not discriminate significantly with other
scales. CONCLUSIONS: Although the Disq-24 satisfied
the equal variance, equal weights, and internal consis-
tency assumptions of summated rating scales, item dis-
criminant validity was not supported in the above analy-
sis. This lack of support could be due to the small sample
size and/or the existence of a unidimensional structure.
The validity of the instrument warrants further testing in
a headache population which is not restricted to chronic
daily headache patients.
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A MODEL FOR PREDICTING THE INCIDENCE
OF MIGRAINE IN THE IDAHO
MEDICAID POPULATION
Shaw J1, Joish V1, Cady PS2
1The University of Arizona, Tucson, AZ, USA; 2Idaho State 
University, Pocatello, ID, USA
BACKGROUND: Migraine headache affects approxi-
mately 9 million Americans. It is a chronic disease and is
often associated with a high rate of disability. OBJEC-
TIVE: The purpose of this research was to develop a
model for predicting the incident number of migraine
cases in the Idaho Medicaid population over a 5-year pe-
riod. METHODS: Incident migraine cases between Janu-
ary 1994 and December 1998 were identified from the
Idaho Medicaid claims database using migraine-specific
ICD-9-CM codes or migraine-specific pharmacy claims.
Data were collected on the total number of new migraine
cases according to age, race, gender, and year. A negative
binomial model was developed to predict incident mi-
graine cases from the other variables. All model indepen-
dents were treated as categorical variables. Two hundred
sixty-six Medicaid recipients between the ages of 5 and
104 were included in the analysis. RESULTS: A test for
